A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Conditions
Colon Cancer · Rectal Cancer · Colorectal Cancer · Colorectal Cancer (CRC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Rocky Mountain Cancer Center - Primary, Denver, Colorado, United States
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
Maryland Oncology Hematology, Columbia, Maryland, United States
Minnesota Oncology Hematology - Primary, Maple Grove, Minnesota, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Oncology Associates of Oregon - Primary, Eugene, Oregon, United States
Northwest Cancer Specialists - Compass, Portland, Oregon, United States
Alliance Cancer Specialists, Wynnewood, Pennsylvania, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Texas Oncology - Central/South Texas, Austin, Texas, United States
Texas Oncology - Gulf Coast, Beaumont, Texas, United States
Texas Oncology - Northeast Texas, Tyler, Texas, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Blue Ridge Cancer Care (Oncology & Hematology Associates of Southwest VA), Salem, Virginia, United States
Study leads
Meredith Pelster, MD
Study Chair
SCRI Oncology Partners